PREECLAMPSIA 401c Tajimuratova I Tashkent Medical Academy DEPARTMENT OF OBSTETRICKS AND GYNECOLOGY SUBJECT: OBSTETRICKS

PREECLAMPSIA Hypertensive disorder specific to pregnancy affects nearly 6% of all pregnancies a major cause of maternal and neonatal mortality and morbidity 15 to 20 % of maternal mortality in developed countries

PREECLAMPSIA Severity ranges from: a mild disorder (transient hypertension in the later part of the pregnancy) to a life-threatening disorder with seizures, HELLP syndrome, fetal hypoxia, and growth retardation more severe disease: 0.56 per 1000 deliveries

PREECLAMPSIA Predisposes women to other serious complications: placental abruption acute renal failure cerebral hemorrhage disseminated intravascular coagulation circulatory collapse

PREECLAMPSIA The etiology is unknown believed to be involved: immune maladaptation placental ischemia oxidative stress genetic susceptibility

PREECLAMPSIA Classification of hypertension in pregnancy Gestational hypertension Preeclampsia / eclampsia Chronic hypertension Preeclampsia superimposed on chronic hypertension

PREECLAMPSIA Definition of hypertension a systolic blood pressure of 140 mmHg or above, or a diastolic blood pressure of 90mmHg or above, on two occasions 6 hours apart Abnormal proteinuria the excretion of 300 mg or more of protein in 24 hours

PREECLAMPSIA Criteria for severe preeclampsia Blood pressure: > 160 mmHg systolic or > 110 mm Hg diastolic Proteinuria: > 5 g in 24 hours Persistent and severe cerebral or visual disturbances (headache, scotoma, blurred vision) Persistent and severe epigastric pain or right upper quadrant pain

PREECLAMPSIA Criteria for severe preeclampsia Pulmonary edema or cyanosis Oliguria (< 500 mL of urine in 24 hours) Eclampsia (grand mal seizures) HELLP syndrome

PREECLAMPSIA Screening tests for gestational hypertension routine components of antepartum care trimester early detection of vasoconstriction early detection of altered renal function early detection of altered hemodynamics detection of placental hypoperfusion / ischemia detection of endothelial activation or injury detection of an activated coagulation / fibrinolytic system

PREECLAMPSIA Prevention of preeclampsia women at risk: multifetal gestation, vascular or renal disease, previous severe preeclampsia-eclampsia, abnormal uterine artery Doppler velocimetry antihypertensive drugs magnesium zinc fish oil calcium low-dose aspirin

PREECLAMPSIA Mild preeclampsia - management < 37 weeks gestation inpatient or outpatient management worsening disease: delivery, magnesium sulfate > 40 weeks gestation delivery, magnesium sulfate weeks gestation inducible cervix: delivery, magnesium sulfate cervix not inducible: inpatient or outpatient management

PREECLAMPSIA Severe preeclampsia - expectant management gestational age: not recommended for 34 weeks gestation hospitalization: tertiary care center antenatal testing: daily

PREECLAMPSIA Severe preeclampsia - guidelines for expedient delivery maternal indications eclampsia, thrombocytopenia, pulmonary edema, acute renal failure persistent severe headache or visual changes elevated liver enzymes with persistent severe epigastric pain or right upper quadrant tenderness labor or rupture of membranes vaginal bleeding, abruptio placenta

PREECLAMPSIA Severe preeclampsia - guidelines for expedient delivery fetal indications repetitive severe variables or late decelerations biophysical profile < 4 on two occasions 4 hours apart amniotic fluid index < 2 cm intrauterine growth restriction fetal death > 34 weeks gestation

PREECLAMPSIA Severe preeclampsia - management protocol admission to labor and delivery for 24 hours magnesium sulfate IV for 24 hours antihypertensives if diastolic blood pressure > 110 mmHg meet guidelines for expedited delivery? yes? delivery

PREECLAMPSIA Severe preeclampsia - management protocol Expedited delivery? no? < 23 weeks: counseling for termination of pregnancy weeks: steroids, antihypertensive medications, daily maternal and fetal evaluation, delivery at 34 weeks weeks: amniocentesis immature fluid - steroids, delivery in 48 hours

PREECLAMPSIA HELLP syndrome - diagnosis 10% before 27 weeks 20% after 37 weeks 70% between 27 and 37 weeks slow initial phase with accelerated final phase versus secondary expression of sepsis, ARDS, renal failure

PREECLAMPSIA HELLP syndrome parameters used to diagnose preeclampsia are not reflective of disease severity target organ systems liver brain kidneys coagulation system increased maternal and perinatal risk

PREECLAMPSIA HELLP syndrome - diagnostic criteria hemolysis abnormal peripheral smear lactate dehydrogenase > 600 U/L elevated liver enzymes serum aspartate aminotransferase > 70 U/L lactate dehydrogenase > 600 U/L low platelets platelet count < 100,000/mm 3

PREECLAMPSIA HELLP syndrome - differential diagnosis acute fatty liver of pregnancy appendicitis diabetes insipidus gallbladder disease gastroenteritis glomerulonephritis hemolytic uremic syndrome hepatic encephalopathy

PREECLAMPSIA HELLP syndrome - differential diagnosis idiopathic thrombocytopenia kidney stones pancreatitis pyelonephritis systemic lupus erythematosus thrombotic thrombocytopenia purpura viral hepatitis

PREECLAMPSIA HELLP syndrome - antepartum management assess and stabilize the maternal condition correct coagulopathy if DIC is present give intravenous magnesium sulfate to prevent seizures provide treatment for severe hypertension to prevent stroke transfer to tertiary center if appropriate if subcapsular hematoma of liver, computed tomography or ultrasound of the abdomen

PREECLAMPSIA HELLP syndrome - antepartum management evaluate fetal well-being non stress test biophysical profile timing of delivery if > 34 weeks gestation, deliver if < 34 weeks gestation, administer corticosteroids, then deliver in 48 hours

PREECLAMPSIA HELLP syndrome - management for cesarean birth use general anesthesia if platelet count is < 75,000 / mm 3 transfuse 5 to 10 units of platelets before surgery if platelet count is < 50,000 / mm 3 leave vesicouterine peritoneum open install subfascial drain

PREECLAMPSIA HELLP syndrome - management for cesarean birth schedule secondary closure of skin incision or subcutaneous drain administer postoperative transfusions as needed perform intensive monitoring for at least 48 hours postpartum consider dexamethasone (10 mg IV every 12 hours) until postpartum resolution of disease occurs

PREECLAMPSIA HELLP syndrome - management of women with a subcapsular liver hematoma general considerations - blood bank aware for potential need of many units of blood general or vascular surgeon consultation avoid direct and indirect manipulation of liver closely monitor hemodynamic status management of hematoma depends on whether it is ruptured or not

PREECLAMPSIA Eclampsia occurrence of convulsions or coma unrelated to other associated conditions all new onset seizures during pregnancy - eclampsia until proven otherwise incidence: 1 in 500 pregnancies 3% in multiple gestations

PREECLAMPSIA Eclampsia precise cause unknown theories vasospasm ischemia edema multisystem organ failure

PREECLAMPSIA Eclampsia seizures usually occur without aura hypertension not severe in 20% edema absent in 30% proteinuria absent in 20% hyperreflexia is not predictive of seizure headache or visual changes - most common precipitating event

PREECLAMPSIA Eclampsia 80% of convulsions occur before or during the delivery 1/3 of cases may be not preventable atypical less than 20 weeks gestation more than 48 hours postpartum

PREECLAMPSIA Eclampsia - risk factors low socioeconomic status extremes in childbearing age African-American no prenatal care substance abuse

PREECLAMPSIA Eclampsia - management control convulsions correction of hypoxia and acidosis blood pressure control delivery after maternal stabilization

PREECLAMPSIA Eclampsia - anticonvulsant therapy magnesium sulfate mechanism of action - smooth muscle relaxation by displacement of calcium dosage g intravenous loading dose, followed by 2 g per hour may be given intramuscularly

PREECLAMPSIA Eclampsia - magnesium sulfate side effects: maternal hypotonia respiratory depression cardiac arrest neonatal depression contraindicated in myasthenia gravis use with caution in renal insufficiency

PREECLAMPSIA Eclampsia - anticonvulsant therapy phenytoin used extensively in Europe may be used in myasthenia gravis mechanism of action - may increase gamma aminobutyric acid- mediated chloride conduction in postsynaptic membranes may inhibit neurotransmitter inhibitory systems

PREECLAMPSIA Eclampsia - phenytoin dosage - 1 g loading dose over 1 hour cardiac monitoring during administration side effects arrhythmias with rapid administration hepatitis Steven-Johnson syndrome

PREECLAMPSIA Eclampsia - diazepam side effects - loss of consciousness, hypotension, respiratory depression caution - may increase risk of aspiration causes prolonged depression of the neonate sodium thiopentotal long acting barbiturate used when sedation, paralysis and intubation needed

PREECLAMPSIA Eclampsia - management of fetus fetal bradycardia during seizure ~ 5 minutes after the onset of the seizure may be associated with rebound tachycardia recovery phase may show late decelerations monitor for uterine hypertonicity allow for fetal recovery monitor for signs of abruption

PREECLAMPSIA Eclampsia - radiographic evaluation should be reserved for women with neurological deficit, recurrent seizures, or atypical presentation abnormal CT findings - 50% edema, hemorrhage, infarction cerebral angiography has limited use 90% of EEG evaluations may be abnormal

PREECLAMPSIA Eclampsia - management allow patient to have seizure use bite block as needed to prevent maternal injury establish airway administer magnesium sulfate as soon as possible obtain arterial blood gases monitor urine output control hypertension

PREECLAMPSIA Counseling regarding future pregnancies - HELLP syndrome information available varies recurrent risk of preeclampsia: 43% (19%) recurrent risk of HELLP syndrome: 19-27% (3%) If HELLP syndrome < 32 weeks recurrent risk of preeclampsia / eclampsia is 61%